AI Article Synopsis

  • Gatifloxacin and moxifloxacin have expanded fluoroquinolone coverage to include specific gram-positive bacteria, offering treatment for a variety of infections beyond the genitourinary system.
  • Most fluoroquinolones have high oral bioavailability, with minimal side effects like nausea and headaches, but some serious risks include QT prolongation and tendon issues.
  • These new antibiotics are not typically first-line treatments and should be used carefully to prevent increasing antibiotic resistance, with mentions of their potential use in biological warfare.

Article Abstract

With the recent introduction of agents such as gatifloxacin and moxifloxacin, the traditional gram-negative coverage of fluoroquinolones has been expanded to include specific gram-positive organisms. Clinical applications beyond genitourinary tract infections include upper and lower respiratory infections, gastrointestinal infections, gynecologic infections, sexually transmitted diseases, and some skin and soft tissue infections. Most quinolones have excellent oral bioavailability, with serum drug concentrations equivalent to intravenous administration. Quinolones have few adverse effects, most notably nausea, headache, dizziness, and confusion. Less common but more serious adverse events include prolongation of the corrected QT interval, phototoxicity, liver enzyme abnormalities, arthropathy, and cartilage and tendon abnormalities. The new fluoroquinolones are rarely first-line agents and should be employed judiciously. Inappropriate use of agents from this important class of antibiotics will likely worsen current problems with antibiotic resistance. Applications of fluoroquinolones in biologic warfare are also discussed.

Download full-text PDF

Source

Publication Analysis

Top Keywords

infections
5
quinolones comprehensive
4
comprehensive review
4
review introduction
4
introduction agents
4
agents gatifloxacin
4
gatifloxacin moxifloxacin
4
moxifloxacin traditional
4
traditional gram-negative
4
gram-negative coverage
4

Similar Publications

Controlled human infection studies accelerate vaccine development.

J Infect Dis

January 2025

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland 21218, USA.

Clinical trials that employ human challenge, also known as controlled human infection models (CHIM), have rapidly advanced vaccine development for multiple pathogens, including at least 30 disease models to date. CHIM studies, championed by networks of researchers, regulators, ethicists, technical experts, and other stakeholders, limit exposure of individuals to an investigational product, de-risk product investments, identify correlates of protection, and most importantly provide a prompt readout of vaccine efficacy. While CHIM studies provide multiple advantages, important challenges exist, including strengthening the relevance and comparability of CHIM study results to efficacy trials in endemic areas, particularly in resource-limited settings.

View Article and Find Full Text PDF

[Approach to Scabies in Children: An Update].

Acta Med Port

January 2025

Serviço de Dermatologia. Unidade Local de Saúde Santo António. Porto. Portugal.

Scabies is a common dermatological infection that globally affects more than 200 million people. It is caused by the parasite Sarcoptes scabiei var. hominis and its transmission primarily occurs through direct contact.

View Article and Find Full Text PDF

Background: In difficult colorectal cases, surgeons may opt for a hand-assisted laparoscopic (HALS) colectomy or attempt a laparoscopic surgery that may require an unplanned conversion to open (LCOS). We aimed to compare the clinical outcomes of these 2 types of surgeries.

Methods: Colectomies for acute diverticulitis with a HALS or LCOS surgery were selected from the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) 2022 Targeted Colectomy Database.

View Article and Find Full Text PDF

Population-level Impact of HPV Vaccination on the Incidence of Genital Warts in Sweden.

J Infect Dis

January 2025

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, SE-17177 Stockholm, Sweden.

Background: Sweden introduced HPV vaccination in 2006, administered through opportunistic, subsidized, catch-up and school-based programs. Notably, genital warts (GW) are the first observable clinical outcome following infection by HPV-6/11, targeted by vaccination. We aim to gain knowledge of the incidence of GW in Sweden and evaluate its change throughout vaccination programs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!